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Abstract 
Background: Anthracyclines, such as doxorubicin (Adriamycin), are highly effective chemo-
therapeutic agents, but are well known to cause myocardial dysfunction and life-threatening 
congestive heart failure (CHF) in some patients.  
Methods: To generate new hypotheses about its etiology, genome-wide transcript analysis was 
performed on whole blood RNA from women that received doxorubicin-based chemotherapy and 
either did, or did not develop CHF, as defined by ejection fractions (EF)<40%. Women with 
non-ischemic cardiomyopathy unrelated to chemotherapy were compared to breast cancer pa-
tients prior to chemo with normal EF to identify heart failure-related transcripts in women not 
receiving chemotherapy. Byproducts of oxidative stress in plasma were measured in a subset of 
patients. 
Results: The results indicate that patients treated with doxorubicin showed sustained elevations 
in oxidative byproducts in plasma. At the RNA level, women who exhibited low EFs after chem-
otherapy had 260 transcripts that differed >2-fold (p<0.05) compared to women who received 
chemo but maintained normal EFs. Most of these transcripts (201) were not altered in 
non-chemotherapy patients with low EFs. Pathway analysis of the differentially expressed genes 
indicated enrichment in apoptosis-related transcripts. Notably, women with chemo-induced low 
EFs had a 4.8-fold decrease in T-cell leukemia/lymphoma 1A (TCL1A) transcripts. TCL1A is ex-
pressed in both cardiac and skeletal muscle, and is a known co-activator for AKT, one of the major 
pro-survival factors for cardiomyocytes. Further, women who developed low EFs had a 2-fold 
lower level of ABCB1 transcript, encoding the multidrug resistance protein 1 (MDR1), which is an 
efflux pump for doxorubicin, potentially leading to higher cardiac levels of drug. In vitro studies 
confirmed that inhibition of MDR1 by verapamil in rat H9C2 cardiomyocytes increased their 








Conclusions: It is proposed that chemo-induced cardiomyopathy may be due to a reduction in 
TCL1A levels, thereby causing increased apoptotic sensitivity, and leading to reduced cardiac 
MDR1 levels, causing higher cardiac levels of doxorubicin and intracellular free radicals. If so, 
screening for TCL1A and MDR1 SNPs or expression level in blood, might identify women at 
greatest risk of chemo-induced heart failure. 
Key words: doxorubicin, adriamycin, heart failure, cardiomyopathy, microarray, expression pro-
filing, free radicals, multidrug resistance protein, MDR1, TCL1A. 
Introduction 
Anthracyclines, such as doxorubicin (Adriamy-
cin), have been key cancer chemotherapeutic agents 
for the past 30 years. Despite their demonstrated 
benefit in cancer chemotherapy, anthracyclines can 
cause myocardial dysfunction in up to 25% of patients 
and life threatening heart failure in 1-4% of patients 
[1]. Cardiotoxicity due to doxorubicin is dose-related, 
with doses exceeding 500 mg/kg associated with the 
greatest incidence of left ventricular (LV) dysfunction 
and development of clinically overt congestive heart 
failure (CHF), often manifest as a reduction in the left 
ventricular ejection fraction (EF) [2]. However, pa-
tients receiving lower doses of doxorubicin also de-
velop evidence of cardiotoxicity, and a wide individ-
ual susceptibility to cardiac damage has been ob-
served.  
Anthracyclines attack tumor cells by intercalat-
ing on DNA, inhibiting DNA replication, and thereby 
generating DNA damage, thus triggering apoptosis. 
Rapidly growing tumor cells are more susceptible 
than non-dividing cells, such as cardiomyocytes and 
neurons, thus conferring a relatively selective an-
ti-tumor effect. However, it is unclear why some 
women are especially sensitive to the toxic effects of 
anthracyclines on cardiomyocytes. The mechanism by 
which anthracyclines produce myocardial damage is 
thought to involve a marked increase in oxidative 
stress, culminating in cardiomyocyte apoptosis. There 
appears to be a subset of individuals who are more 
susceptible to drug-induced oxidative damage and 
apoptosis. This susceptibility appears to be exacer-
bated with the use of trastuzumab, a monoclonal an-
tibody to the HER2 proto-oncogene, a member of ep-
idermal growth factor (EGF) receptor family. The ad-
dition of trastuzumab to anthracycline therapy has 
been shown to improve the chemotherapeutic re-
sponse, but is also associated with a marked increase 
in the development of CHF [3], with the incidence of 
CHF increasing from 8% to 27% when trastuzumab 
was added [4]. Thus, the identification of women 
prone to CHF after chemotherapy is key to tipping the 
balance between effective chemotherapy and poten-
tially life-threatening adverse effects. 
A growing literature indicates that changes in 
gene expression of circulating cells can reflect changes 
in other organ systems. Published studies have doc-
umented mRNA expression changes in blood in dis-
ease states such as vasculitis [5], lupus [6], and coro-
nary artery disease [7; 8]. The potential of this meth-
odology in heart failure research has recently been 
reviewed by Liew [9]. Thus, the present studies were 
designed to identify mRNA expression markers in 
patient’s blood and to determine whether any of the 
markers might elucidate possible mechanisms of en-
hanced susceptibility to anthracycline-induced cardi-
otoxicity. Minimally, biomarkers of chemo-induced 
CHF could allow individualization of chemotherapy, 
and importantly, administration of potentially pre-
ventive medications such as angiotensin receptor 
blockers, anti-oxidants, and beta-blockers. 
Methods 
Subjects  
Patients at The George Washington University 
Medical Faculty Associates presenting for treatment 
of cancer using anthracyclines as part of a chemo-
therapeutic protocol, with or without adjuvant 
trastuzumab, were enrolled in an Institutional Review 
Board-approved protocol and gave informed consent. 
Inclusion/Exclusion Criteria  
All women presenting for anthracycline-based 
chemotherapy were considered eligible. Patients were 
excluded if their pre-chemo evaluation indicated ab-
normal left ventricular systolic function (ejection frac-
tion < 50%), past history of, or active cardiac disease 
including: myocardial infarction, congestive heart 
failure, angina pectoris requiring medication, ar-
rhythmia requiring medication, clinically significant 
valvular disease (i.e., valvular stenosis of any degree, 
regurgitation greater than mild in severity), or un-
controlled systemic hypertension. 
Echocardiography 
A standard two-dimensional and Doppler study, 
including tissue Doppler imaging, was performed at 




baseline, prior to receiving chemotherapy. Left ven-
tricular systolic function was assessed using biplane 
Simpson’s method for calculation of ventricular 
volumes and EF. Echocardiograms were repeated 
after completion of the chemotherapy protocol, or if 
the patient developed clinical symptoms of heart 
failure. 
Assessment of LV Diastolic Function 
Diastolic function was evaluated by pulsed and 
tissue Doppler for estimation of pulmonary capillary 
wedge pressure (PCWP) using the formula (PCWP= 
1.24 [E/Ea] + 1.9) [10], and color tissue Doppler as-
sessment for diastolic dyssynchrony [11]. Echocardi-
ography and pre-defined parameters were repeated 
immediately after the final cycle of anthracyclines 
(typically 8 weeks), 6 months and 12 months. Patients 
receiving additional chemotherapy with trastuzumab 
also underwent clinically indicated echocardiograms 
prior to initiation of therapy, then at 6 months and 12 
months. 
Markers of Oxidative Stress 
Blood samples were obtained prior to chemo-
therapy, and 24 hours following completion of each 
infusion cycle. Accumulation of lipid peroxidation 
products in the blood were assessed 
semi-quantitatively by the measurement of thiobar-
bituric-acid reactive substances (TBARS), as described 
[12]. Briefly, fresh plasma was acidified with trichlo-
roacetic acid to prevent post-isolation changes and 
then reacted with 2-thiobarbituric acid and butylated 
hydroxytoluene at 80˚ C for 30 min, and the chromo-
phore developed in the supernatant was measured at 
532 nm. 
Blood RNA Isolation 
Blood was collected by venipuncture directly 
into PaxGene Blood RNA collection tubes (PreAna-
lytiX). The blood was incubated 2 hours at 25˚ C to 
complete the cell lysis and RNAse neutralization, 
moved to -20˚ C overnight, and then stored at -80˚ C 
until processing. Whole blood RNA was isolated us-
ing the PaxGene blood RNA isolation system with 
on-column DNAse treatment. RNA samples were 
further purified for microarray analysis using RNAe-
asy Mini kit (Qiagen). RNA concentration was quan-
titated by absorbance at 260 nm (Nanodrop), and the 
RNA integrity was tested by capillary electrophoresis 
on an Agilent 2100 Bioanalyzer. The typical yield of 
RNA was ~7 µg/2.5 ml whole blood. 
Microarray Data Analysis 
Purified RNA (100 ng) was reverse transcribed 
with SuperScript III using random hexamers and the 
cDNA was amplified with Ovation RNA Amplifica-
tion System V2 kit (NuGEN). The cDNA was further 
purified with DNA Clean & Concentrator-25 (Zymo 
Research), and then 3.75 µg of cDNA was fragmented 
and labeled with FL-Ovation cDNA Biotin Module V2 
kit (NuGEN) and hybridized to an Affymetrix 
GeneChip Human Genome U133 Plus 2.0 Array for 18 
hours. The hybridization of fluorescently labeled 
cDNA was quantitated on an Affymetrix GeneChip 
Scanner 3000 7G. 
Statistical Methods 
The microarray probeset levels were converted 
to transcript levels using RMA summarization in 
GeneSpring GX 10 (Agilent Technologies). To identify 
transcripts associated with chemo-induced CHF, the 
54,000 total transcripts were analyzed by an unpaired 
t-test (p-value cut-off ≤ 0.05), and further filtered for a 
fold-change of >1.5 between groups. To understand 
the possible relationships between these transcripts, 
the differentially expressed gene (DEG) list was im-
ported into Ingenuity Pathway Analysis (IPA) soft-
ware. Functional annotation and gene ontology of 
DEGs was further explored with DAVID [13]. 
Genotyping Analysis 
DNA from subjects was purified from Paxgene 
preserved whole blood by centrifugation of 500 µl and 
treating the pellet with RNAse/proteinase K followed 
by phenol/chloroform extraction and ethanol precip-
itation [14]. SNPs in TCL1A were determined by 
TaqMan assay for the rs11849538 SNP on an ABI 7300, 
with dissociation temperature of 95˚C and annealing 
temperature of 60˚C. From the 24 patients for which 
expression data was obtained, sufficient DNA and 
genotyping results were obtained from 18 of the pa-
tients, including all 5 patients in the chemo-induced 
low EF group. 
Cell culture 
Rat cardiomyocyte progenitors (H9C2) were 
obtained from American Type Culture Collection 
(ATCC) and maintained in DMEM with 10% FBS and 
antibiotics. The MDR1 inhibitor, verapamil (Sigma), 
was tested by plating cells at 50,000 cells/well of a 24 
well plate and allowing them to adhere overnight. 
Verapamil was added 2 hours prior to the addition of 
doxorubicin at specified doses. After 20 hours with 
doxorubicin, the viable cells were quantitated by their 
ability to metabolize MTT as described [15]. Briefly, 
the culture media was replaced with MTT for 4 hours 
and the metabolic product was quantified by dis-
solving the cells in 200 µl of DMSO and transferring 
the media to a 96 well plate, where absorbance at 570 




nm was determined in a plate spectrophotometer. 
Results 
To generate new hypotheses about the etiology 
of chemo-induced CHF, we performed genome-wide 
transcript analysis with the Affymetrix U133+2 
GeneChip on whole blood RNA from women receiv-
ing chemotherapy with anthracyclines who either did 
(Group A, n=5), or did not (Group B, n=10) develop 
subsequent cardiac dysfunction, as defined by ejec-
tion fractions (EF)<40%. Women with non-ischemic 
cardiomyopathy not due to chemotherapy (Group C, 
n=4) were compared to breast cancer patients prior to 
chemo with normal EF (Group D, n=5) to identify 
heart failure-related transcripts independent of 
chemotherapy. The general experimental design is 
summarized in Figure 1. 
Clinical Parameters 
 Demographic and baseline cardiovascular pa-
rameters are shown in Table 1. While increasing age 
has been reported to be associated with reduced LV 
performance after chemotherapy [16], there was no 
significant difference in age between women who did 
or did not develop HF after chemo in our cohort 
(p>0.05). There were more women in Group D with 
hypertension and diabetes, but with the small group 
size, the difference was not statistically significant. 
 A comparison of the two-dimensional echo im-
ages of a patient with normal LV systolic function 
versus a patient with chemo-induced dilated cardio-
myopathy is shown in Additional file 1: Supplemen-
tary Figure 1. In the patient with normal LV function, 
the heart size is normal in diastole and decrease nor-
mally in systole, reflecting a normal EF. In contrast, 
with chemo-induced cardiomyopathy, the heart is 
dilated and shows little change in size with systolic 




Fig 1. Experimental design. Women with, and without breast cancer 
gave informed consent and were enrolled in the study. Some women with 
breast cancer given doxorubicin-containing chemotherapy developed 
clinically significant low ejection fractions (EF) (Group A) and were com-
pared to similar women who did not develop low EF (Group B). To identify 
transcripts correlating with CHF, independent of chemotherapy, women 
with breast cancer and normal ejection fractions, were sampled prior to 
chemotherapy (Group D), and compared with women who developed low 





Table 1. Classification and Baseline Values of Patients. 
Group A B C D  
Name BrCa-Chemo-Low EF BrCa-Chemo-Norm EF No Ca-NoChemo-Low EF BrCa-preChemo-Norm EF  
N= 5 10 4 5  
Breast Cancer Yes Yes No Yes  
Chemotherapy Yes Yes No No  
Low Ejection Fraction Yes No Yes No  
Age (mean) 59.2 58.3 53.4 48.1 NS 
Age (median, range) 56(51-80) 60(42-76) 51(47-63) 53(43-58)  
Ejection Fraction (EF) 24.8 60.9 26.6 68.0 p<.001 
EF (median, range) 20(15-40) 58(52-69) 24(22-35) 66(55-86)  
Hypertensive 0% 0% 0% 40% NS 
Diabetic 0% 0% 0% 20% NS 
 
 








Gene Expression Profiling of Whole Blood 
RNA 
Expression profiling of blood indicates that 
women who developed a low EF after chemotherapy 
had 260 transcripts that differed >2-fold, with a t-test 
probability of p<0.05, compared to women receiving 
chemo who maintained normal EFs (A vs. B). Most of 
these transcripts (201) were not shared by women 
who developed low EFs independent of chemother-
apy (C vs. D). As shown in Figure 2, the 201 tran-
scripts that differentiate the chemo-induced low EF 
women (A) from women similarly treated, but re-
taining normal EF (B), tend to be more 
down-regulated (blue) than up-regulated (red). 
However, these differentially expressed transcripts 
are not similarly regulated in women with low EFs 
who never received chemo (C). However, 59 tran-
scripts were identified that were differentially ex-
pressed in both chemo-dependent (A vs. B) and 
chemo-independent low EFs (C vs. D), suggesting 
these transcripts report some general cause or effect of 
low EFs (Additional file 2: Supplementary Tables 1 
and 2). Selected transcripts from the 201 gene list, or-
ganized by putative function, are shown in Table 2, 
and discussed below. 
Functional annotation: Analysis of the DEG list 
in DAVID and IPA helped to identify relationships 
between the transcripts. In the ‘biological processes’ 
category, 18 terms were statistically overrepresented, 
with transcripts mainly categorized into cellular acti-
vation, cellular proliferation, immune response, dif-
ferentiation, signal transduction, and drug re-
sponse/transport. With additional manual annota-
tion, several general pathways with potential rele-
vance to heart failure emerged. 
Apoptosis: Among the DEGs unique to 
chemo-induced low EFs, there were notable changes 
in apoptosis-related transcripts. There was decreased 




expression of BIRC3, which is a member of the inhib-
itor of apoptosis protein family (cIAP2, IAP-C, 
MIHC), which are ubiquitin ligases that target the 
degradation of the TNF receptor interacting protein 
(RIP)[17]. Conversely, there was decreased expression 
of the proapoptotic caspase 8 associated protein 2 
(CASP8AP2, FLASH, Flice-associated huge protein), 
which facilitates caspase 8 activation by TNF receptor 
or fas [18]. Interestingly, CASP8AP2 has been identi-
fied as mediating the cardiac ischemic precondition-
ing effect of mir210 [19]. PLAG1, decreased more than 
3-fold, is a proto-oncogene transcription factor that 
regulates numerous apoptotic signals [20].  
 
 
Fig 2. Clustered heatmap of transcripts associated with chem-
otherapy-induced heart failure. Transcript profiles of blood from 
women with breast cancer who did (Group A) or did not (Group B) 
develop low EFs were compared to identify differentially-expressed genes 
(DEGs) by a combined fold-change (>1.5 fold) and t-test (p<0.05) filtering. 
To exclude transcripts that were associated with heart failure in women 
not receiving doxorubicin, women with breast cancer and normal cardiac 
performance were sampled prior to chemotherapy (Group D) and com-
pared to women with low EFs but who never received chemotherapy 
(Group C). The resulting 201 transcripts were clustered by their expres-
sion pattern across the 4 groups with each row indicating one transcript. 
Red indicates increased expression, blue indicates decreased expression, 
with yellow indicating little or no change. 
Notably, women with chemo-induced low EFs 
had a 4.8-fold decrease in the oncogene T-cell leuke-
mia/lymphoma 1A (TCL1A). TCL1A is expressed in 
both cardiac and skeletal muscle, and is a known 
co-activator for AKT, one of the major pro-survival 
factors for cardiomyocytes. Additionally, ge-
nome-wide SNP analysis has previously identified 
TCL1A SNPs strongly associated with musculoskele-
tal adverse events in women receiving aromatase in-
hibitors (AI) [21]. The variant allele at rs11849538 is 
quite common (22-34% heterozygous, 6% homozy-
gous), and creates a new estrogen receptor-binding 
site [21].  
Immune-related: Considering that whole blood 
was profiled, it is reasonable that the majority of dif-
ferentially-expressed transcripts fall into im-
mune-related categories, particularly T-cell and B-cell 
activation and proliferation. However, recent data has 
suggested that hyper-activated innate immune re-
sponses could contribute to the progression of CHF 
(reviewed in [22]). Notably, there was a 2.5-fold in-
crease in the interleukin-3 receptor (IL3R), and an 
8-fold decrease in IL-8, a change twice as large as any 
other transcript. Expression levels in general, howev-
er, did not support a general activation of innate im-
munity in circulating cells, with consistent 
down-regulation of B-cell activation markers 
(BANK1, CD79A), Fc-like receptors (FCRL1, FCRL2), 
and two interferon-responsive transcripts (IFI44, 
RTP4/IFRG28). However, elevated expression of 
HLA-DQB2 could suggest some type of autoimmune 
reaction triggered by chemotherapy, because SNPs in 
DQB2 have been associated with rheumatoid arthritis 
[23] and lupus [24]. 
Electrolyte transporters: Another potential ex-
planation for the increased cardiotoxicity in some 
women would be if there were inherited or acquired 
defects in membrane transporters for electrolytes, 
which could create performance deficits that would 
then be exacerbated by chemotherapy, leading to cell 
death. There were noticeable changes in four electro-
lyte channels: chloride channel 4 (CLCN4), Nav1.3 
sodium channel (SCN3A), and two voltage-gated po-
tassium channels (KCNH8, KCNQ5). 
Signaling/Detoxifying Enzymes: Interestingly, 
the microsomal epoxide hydrolase (EPHX1), which is 
a known xenobiotic metabolizing enzyme for 
by-products of doxorubicin, was elevated 2.2-fold in 
the chemo-CHF group. Prior genotyping studies ob-
served that EPHX1 polymorphisms were associated 
with both breast cancer risk and overall survival after 
therapy [25]. PEX6 was elevated 2-fold and plays a 
key role in the assembly of the peroxisome. Defects in 
PEX6 lead to elevated free radicals and cellular ne-




crosis [26], suggesting that elevated PEX6 may be a 
compensatory response to increased free radical lev-
els. Prostaglandin D2 synthase (PTGDS) mRNA was 
elevated 2.1-fold in the chemo-CHF cases, and the 
PTGDS protein has recently been reported as a circu-
lating biomarker in coronary artery disease [27; 28] 
and PTGDS mRNA is elevated in epicardial adipose 
tissue of patients with coronary disease [29]. 
Drug Transport: Among the most straightfor-
ward explanations for increased cardiotoxicity would 
be elevated cardiac levels of doxorubicin, possibly 
secondary to decreased multidrug resistance proteins 
in the cardiac tissue. Thus, it is interesting that both 
multidrug resistance protein 1 (MDR1, 
p-glycoprotein, ABCB1) and MDR2/3 (ABCB4) 
mRNAs in blood were decreased more than 2-fold in 
the chemo patients that developed low EFs. MDR1 is a 
well-established efflux pump for doxorubicin [30]. 
Elevated levels of MDR1 in tumor cells [31], and 
promoter SNPs that increase MDR1 expression, are 
commonly part of the chemotherapy-resistant phe-
notype [32]. Acute cardiotoxicity of doxorubicin has 
previously been linked to G671V variants of MDR1 in 
case-control studies [33]. While it is well known that 
doxorubicin is a substrate for MDR1, recent in vitro 
analysis also suggests that this coding variant de-
creases the efflux of free radical adducts from cells 
[34]. Thus, if cardiac levels of MDR1 and MDR2/4 
were reduced in parallel to the blood levels, the cells 
may experience both elevated doxorubicin levels and 
elevated retention of the induced free radicals. 
Free Radical Levels 
 To determine whether doxorubicin caused ele-
vations in free radical formation, a substudy was 
conducted on patients in which plasma samples were 
obtained pre-chemo, and 24 hours after at least five 
chemo cycles. As shown in Figure 3, plasma TBARS 
increased up to 2.5-fold after chemotherapy in some 
patients, with average levels elevated 64% in the four 
patients evaluated (ANOVA p<0.01). Despite elevated 
free radicals, none of these patients developed car-
diomyopathy or low EF within the study period. This 
confirms prior data demonstrating elevated plasma 
TBARS post-chemo [35], and extends it to demon-
strate that the elevations are sustained over five 
chemo cycles. 
Genotyping Analysis 
The almost 5-fold reduction in TCL1A mRNA 
levels in the chemo-CHF group suggested that it 
might contribute to increased cardiac apoptosis. Ge-
nome-wide SNP analysis has previously identified 
TCL1A SNPs strongly associated with musculoskele-
tal adverse events in women receiving aromatase in-
hibitors (AI) [21]. The variant allele (G) at rs11849538 
is quite common (HapMap variant allele frequency of 
8-43%), and creates an estrogen receptor-binding site. 
However, genotyping for this SNP in 18 patients, in-
cluding all of the women with chemo-induced low 
EFs (Group A), did not detect differential variant al-
lele frequencies, with essentially all groups near 40% 
(not shown). 
Effect of MDR1 inhibition on response to dox-
orubicin in vitro 
To determine whether the reduced MDR1 could 
have a functional effect on cardiomyocyte survival, 
H9C2 rat embryonic cardiomyocytes were pretreated 
with verapamil (0-100 µM), a known MDR1 inhibitor 
with an effective IC50 of 120 µM [36], 2 hours prior to 
low doses of doxorubicin (0-50 µM). Pretreatment 
with verapamil significantly enhanced the toxicity of 
doxorubicin (ANOVA p<0.001 for both main effects 
and interaction), which was significant in pairwise 
testing at the combined doses of 50-100 µm verapamil 
and 10-50 µM doxorubicin in H9C2 cardiomyocytes 
(Figure 4). This confirms prior studies indicating that 
inhibition of MDR1 activity by verapamil increases 




Fig 3. Plasma levels of free radical modifications to protein. A 
small group of patients were followed prior to doxorubicin-based chem-
otherapy and then after multiple cycles of chemotherapy. Plasma samples, 
pre-chemo, and 24 hours after each chemo cycle, were specially preserved, 
stored at -80˚ C, and then analyzed for products of oxidative modification. 
Thiobarbituric-acid reactive substances (TBARS) in plasma are shown for 
pre-chemo (Base) and 5 subsequent chemo cycles (error bars = s.e.m.). 
The main effect of chemotherapy on TBARS, expressed as a percent of 
baseline values, was evaluated by ANOVA (p=0.01), and asterisks indicate 
where post-hoc t-tests were significant compared to pre-chemo baseline 
(** p<0.01, * p<0.05, n=4). 





Fig 4. The effect of MDR1 inhibition on doxorubicin-induced cell 
death. Rat H9C2 cardiomyocytes were pretreated with the MDR1 
inhibitor verapamil for 2 hours at the specified doses (0-100 µM). Cells 
were then treated with increasing doses of doxorubicin (0-50 µM) and cell 
survival was determined 20 hours later by measuring their metabolic 
reduction of MTT, with the product measured by O.D. at 570 nm 
(n=3/group, error bars = s.e.m.). Asterisk indicates a significant change 
between verapamil treated and untreated (p<0.05). 
 
Discussion 
The general mechanisms of chemo-induced heart 
failure have been extensively studied and two major 
etiologies have emerged: 1) direct damage to the car-
diomyocyte’s DNA, triggering apoptosis, and 2) in-
duction and accumulation of cellular free radicals 
causing toxicity and cardiomyocyte death. However, 
the particular inter-individual variations that affect 
the susceptibility to chemo-induced CHF are poorly 
understood. Pretreatment variables, such as age and 
left ventricular EF have been identified as predictors 
of the adverse cardiac response to epirubicin, sug-
gesting that a pre-existing, but compensated cardiac 
performance deficit may increase the susceptibility to 
chemotherapy-induced damage [16]. 
Several lines of evidence suggest that the sur-
vival/apoptosis pathways are a major determinant of 
the cardiac outcome after doxorubicin. In rat neonatal 
cardiomyocytes, overexpression of the apoptosis reg-
ulator ARC inhibits doxorubicin-induced death, while 
siRNA to ARC increases apoptosis induced by doxo-
rubicin [41], suggesting that doxorubicin induces 
death via caspase-dependent mechanisms. In a rat 
model, intracoronary AKT1 gene delivery mitigates 
doxorubicin-induced reductions in fractional short-
ening, and improves LV function at five weeks 
post-treatment [42]. The apparent increase in cardio-
toxicity associated with obesity led to pre-clinical 
studies in which adiponectin was shown to reduce 
cardiac dysfunction after doxorubicin by its ability to 
stimulate AKT activity [43]. Likewise, microarray 
analysis of cardiac tissue in mice developing LV dys-
function after doxorubicin treatment showed changes 
in transcripts associated with hypertrophy (STARS), 
ATP levels (SNF1-kinase), and apoptosis, (AXUD1, a 
downstream target of AXIN1) [44]. Thus, the cardiac 
levels of TCL1A may be a critical determinant of AKT 
activity in the cardiomyocytes, and thus a key factor 
in susceptibility to doxorubicin cardiotoxicity. It is 
interesting to speculate that the reduced blood levels 
of TCL1A might be related to the known effect of Ep-
stein-Barr Virus (EBV) latent membrane protein1 
(LMP1), which suppresses TCL1A levels via miRNA 
29-b [45]. 
The second major pathway of cardiac damage, 
free radical injury, is influenced by changes in anti-
oxidant systems, and variations in the efflux pumps 
for doxorubicin and the free radicals that it creates. 
Polymorphisms in ABCB1/MDR1, such as C3435T, 
are known to affect mRNA levels in breast cancer 
specimens [46] and may be related to therapeutic 
outcome from anthracyclines [32; 47], possibly by af-
fecting mRNA stability [48]. However, the relation-
ship between MDR1 polymorphisms and mRNA ex-
pression or drug transport remains complicated [49]. 
For instance, cardiac levels of MDR1 are affected by 
an exon 21 polymorphism, but not by the C3435T SNP 
[50]. Transgenic mice overexpressing MDR1 selec-
tively in the myocardium are protected from damage 
inflicted by doxorubicin [51]. Further, knockout of 
heat shock factor 1 (HSF1) increased the expression of 
MDR1 in the heart, increased efflux of doxorubicin, 
and reduced mortality [40]. MDR1 levels could be 
modulated by AKT activity because signaling through 
phosphoinositide 3-kinase (PI3K) and AKT can in-
crease MDR1 expression [52], which is consistent with 
the reduction in both TCL1A and MDR1 in the pre-
sent studies. Recent data in experimental models has 
suggested that one important factor might be the im-
pact of the chemotherapy on the cardiac 
stem/progenitor cells. When syngeneic cardiac pro-
genitors were reintroduced post-chemo in mice, car-
diac performance was restored [53]. It is worth noting 
that MDR1 protein is considered one of the key 
markers of cardiac stem cells [54]. 
The present studies have several limitations that 
deserve recognition. First, this is a relatively small 
sample size, with only five women who have 
chemo-induced low EFs: a consequence of the fact 
that oncologists have been aware of this complication 
and reduce the chemo dosages to render this a rela-




tively rare side effect. Second, of necessity, the studies 
employed a surrogate marker for expression profiling, 
peripheral blood, which may or may not reflect the 
expression profile in the heart. Based on the present 
studies, it would be important to investigate whether 
cardiac MDR1 levels, or MDR-like efflux activity, are 
predictive of cardiomyopathy after chemotherapy. 
Third, because of the low incidence of chemo-induced 
HF, it was impractical to sample patients prior to the 
initiation of chemo, and then follow them to deter-
mine differences between women who did, of did not 
develop low EFs. Rather, it was more practical to 
sample patients with low EFs after chemotherapy, 
and compare them with patients with normal EF. The 
general effect of low EF on expression profiles was 
then determined, and subtracted, by analyzing 
non-chemo patients with low EF. 
 
 
Fig 5. Schematic model of TCL1A and MDR1 effects on the 
cardiac response to chemotherapy. Doxorubicin and related an-
thracyclines intercalate on DNA and induce DNA damage, as well as 
inducing free radical production, combining to preferentially induce the 
death of rapidly dividing tumor cells. However, cardiomyocytes may also 
undergo apoptosis, leading to decreased cardiac performance, and addi-
tional stress on the remaining cardiomyocytes. The present studies suggest 
that reduced cardiac expression of TCL1A leads to a reduced survival and 
protective effect of AKT1, making the cells more sensitive to apoptosis. 
Further, reduced cardiac expression of TCL1A/AKT could lead to reduced 
ABCB1/MDR1, and ABCB4, drug efflux pumps for doxorubicin, which 
would be expected to increase the intracellular levels of doxorubicin, as 
well as reducing the ability of the cardiomyocytes to export the free 
radicals that doxorubicin induces. 
 
Conclusions 
Doxorubicin-induced cardiotoxicity remains a 
devastating complication of a potentially life-saving 
drug. As summarized in Figure 5, it is proposed that 
chemo-induced cardiomyopathy may be due to a ge-
netic predisposition or progressively acquired ten-
dency to reduced TCL1A levels, reducing AKT activ-
ity and thereby causing increased apoptotic sensitiv-
ity to doxorubicin. Furthermore, it is possible that 
coincidental or AKT-related changes in MDR1 levels 
in the myocardium decrease the efflux of doxorubicin, 
thereby causing its accumulation, along with toxic 
free radicals in the cardiomyocytes. Future studies 
will be needed to determine whether screening for 
blood levels of TCL1A and MDR1 mRNA are helpful 
to identify women at greatest risk of chemo-induced 
heart failure. 
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